Jacob "Jack" J.H. Bleesing, MD, PhD
- Co-Director, Diagnostic Immunology Laboratories
- Associate Director, Immunodeficiency and Histiocytosis Program
- Professor, UC Department of Pediatrics
- jack.bleesing@cchmc.org
- Board Certified
About
MD: University of Leiden, Leiden, The Netherlands, 1989.
PhD: University of Leiden, Leiden, The Netherlands, 2002.
Residency: Pediatrics, University of Florida, Gainesville, Florida, 1993.
Fellowship: Allergy/Immunology, Duke University Medical Center, Durham, North Carolina, 1995.
Fellowship: Clinical Laboratory Immunology, National Institutes of Health, Bethesda, Maryland, 2001.
Interests
Immunobiology; translational research; immunologic methods development
Services and Specialties
Cancer and Blood Diseases, Immune Deficiencies and Histiocytosis, Bone Marrow Transplantation BMT, Leukemia, Hemophagocytic lymphohistiocytosisHLH, Rare Lung Diseases
Interests
Clinical investigation of primary immunodeficiency disorders (with emphasis on disorders of immuno dysregulation and B-cell disorders); immuno-reconstitution following blood and marrow transplantation; diagnostic immunology (with emphasis on flow cytometry)
Additional Languages
Dutch, German
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Autoimmune Lymphoproliferative Syndrome (ALPS) Disease and ALPS Phenotype: Are They Two Distinct Entities?. HemaSphere. 2023; 7.
A human STAT3 gain-of-function variant confers T cell dysregulation without predominant Treg dysfunction in mice. JCI insight. 2022; 7.
Reduced Intensity Conditioning Allogeneic Transplant for SCID Associated with Cartilage Hair Hypoplasia. Journal of Clinical Immunology. 2022; 42:1604-1607.
Gain-of-function defects in toll-like receptor 8 shed light on the interface between immune system and bone marrow failure disorders. Frontiers in Immunology. 2022; 13.
Preemptive hematopoietic cell transplantation for asymptomatic patients with X-linked lymphoproliferative syndrome type 1. Clinical Immunology. 2022; 237.
Ruxolitinib for the Treatment of Chronic GVHD and Overlap Syndrome in Children and Young Adults. Transplantation. 2022; 106:412-419.
T-follicular helper cell expansion and chronic T-cell activation are characteristic immune anomalies in Evans syndrome. Blood. 2022; 139:369-383.
International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. Journal of Allergy and Clinical Immunology. 2022; 149:410-421.e7.
Graft rejection markers in children undergoing hematopoietic cell transplant for bone marrow failure. Blood Advances. 2021; 5:4594-4604.
Daratumumab for the management of autoimmune cytopenias in children and young adults: a case series. British Journal of Haematology. 2021; 194:e84-e89.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2022 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent patient satisfaction company, NRC Health. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey